Cetylpyridinium chloride as a part of a combined medication for adults and children during the COVID-19 pandemic: established and perspective use

1. Outbreak of coronavirus infection COVID-19 (Electronic resource.) URL: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019 (access date: 28.09.2021) (in Russ.). 2. Nikolaeva S.V., Gorelov A.V., Ponezheva Zh.B., Akimkin V.G. Clinical and epidemiological characteristics of COVID-19 in children. Proceedings of the International Scientific and Practical Conference on Counteracting New Coronavirus Infection and Other Infectious Diseases. Saratov, 2020 (in Russ.). 3. Nikolaeva S.V., Gorelov A.V., Ponezheva Zh.B., Akimkin V.G. COVID-19 in children in the Russian Federation — the results of the year. Infectious diseases in the modern world: evolution, current and future threats. Proceedings of the XIII All-Russian Congress on Infectious Diseases named after V.I. Academician V.I. Pokrovsky; IV All-Russian Scientific and Practical Conference; VI All-Russian Symposium. M., 2021 (in Russ.). 4. Novikova Yu.Yu., Ovsyannikov D.Yu., Abramov D.S. et al. Children’s multisystem inflammatory syndrome associated with novel coronavirus infection (COVID-19): a study guide. Ed. D.Yu. Ovsyannikova, E.E. Petryaikina. M.: RUDN; 2020 (in Russ.). 5. Hoste L., van Paemel R., Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021;180(7):2019-2034. DOI: 10.1007/s00431-021-03993-5. 6. Rowley A.H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20(8):453–454. DOI: 10.1038/s41577-020-0367-5. 7. Melekhina E.V., Nikolaeva S.V., Zybina T.Yu. et al. A case of multisystem inflammatory syndrome associated with SARS-Cov2 in an 8-year-old child. Pediatrics. G.N. Speransky. 2020; 99 (6): 253–258 (in Russ.). 8. Miller E., Waight P.A., Andrews N.J. et al. Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. J Infect. 2021;83(4):483–489. DOI: 10.1016/j.jinf.2021.07.037. PMC8325949. 9. Telle K., Jørgensen S.B., Hart R. et al. Secondary attack rates of COVID-19 in Norwegian families: a nation-wide register-based study. Eur J Epidemiol. 2021;36(7):741–748. DOI: 10.1007/s10654-021-00760. 10. Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives — A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75(10):2445–2476. DOI: 10.1111/all.14462. 11. Meng Z., Wang T., Chen L. et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem. 2021;21(10):920–927. DOI: 10.2174/1568026621666210429083050. 12. Köntös Z. Efficacy of "Essential Iodine Drops" against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). PLoS One. 2021;16(7):e0254341. DOI: 10.1371/journal.pone.0254341. 13. Chrzanowski J., Chrzanowska A., Graboń W. Glycyrrhizin: An old weapon against a novel coronavirus. Phytother Res. 2021;35(2):629–636. DOI: 10.1002/ptr.6852. 14. Instructions for the medical use of the drug Grammidin for children (spray for topical use, dosed). (Electronic resource.) URL: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-004699/InstrImg_2021_8_25_1472455/%D0%9B%D0%209F_46–0099 .pdf (access date: 28.09.2021) (in Russ.). 15. Instructions for the medical use of the drug Grammidin for children (tablets for resorption). (Electronic resource.) URL: https://cdn.pharm- portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-002179/InstrImg_2021_8_4_1471577/%D0%9B%D0%9F-002179[2013]_0.pdf (access date: 28.09.21) (in Russ.). 16. Mao X., Auer D.L., Buchalla W. et al. Cetylpyridinium Chloride: Mechanism of Action, Antimicrobial Efficacy in Biofilms, and Potential Risks of Resistance. Antimicrob Agents Chemother. 2020;64(8):e00576–20. DOI: 10.1128/AAC.00576-20. 17. Li Z.Y., Meng L.Y. The prevention and control of a new coronavirus infection in department of stomatology. Zhonghua Kou Qiang Yi Xue Za Zhi. 2020;55(0):E001. 18. Izzetti R., Nisi M., Gabriele M. et al. COVID-19 Transmission in Dental Practice: Brief Review of Preventive Measures in Italy. J Dent Res. 2020;99(9):1030–1038. 19. Gherlone E., Polimeni A., Fiorile F. et al. Iandolo R & Technical-Scientifical commission of the Italian Ministry of Health. Operative Guidelines for the dental activity during phase 2 of the COVID-19 pandemic. [cited 15 Jul 2021]. 20. Simon M., Veit M., Osterrieder K. et al. Surfactants — compounds for inactivation of SARS-CoV-2 and other enveloped viruses. Curr Opin Colloid Interface Sci. 2021:101479. DOI: 10.1016/j.cocis.2021.101479. 21. Centers for Disease Control and Prevention, Guidance for Dental Settings. (Electronic resource.) URL: https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html (аccessed: 28.09.2021). 22. American Dental Hygienists’ Association, ADHA Interim Guidance on Returning to Work. (Electronic resource.) URL: https://www.adha.org/resources-docs/ADHA_TaskForceReport.pdf (аccessed: 28.09.2021). 23. Alvarez D.M., Duarte L.F., Corrales N. et al. Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts. Antiviral Res. 2020;179:104818. DOI: 10.1016/j.antiviral.2020.104818. 24. Seo H.W., Seo J.P., Cho Y. et al. Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly. Virus Res. 2019;263:102–111. DOI: 10.1016/j.virusres.2019.01.004. 25. Zhang Z.R., Zhang H.Q., Li X.D. et al. Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening. Antiviral Res. 2020;182:104884. DOI: 10.1016/j.antiviral.2020.104884. 26. Patton L.L. Current strategies for prevention of oral manifestations of human immunodeficiency virus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(1):29–38. DOI: 10.1016/j.oooo.2015.09.004. 27. Popkin D.L., Zilka S., Dimaano M. et al. Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo. Pathog Immun. 2017;2(2):252–269. DOI: 10.20411/pai.v2i2.200. 28. Green A., Roberts G., Tobery T. et al. In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzyme and proteins against a human coronavirus. bioRxiv. 2020(10);28:359257. DOI: 10.1101/2020.10.28.359257. 29. Meyers C., Robison R., Milici J. et al. Lowering the transmission and spread of human coronavirus. J Med Virol. 2021;93(3):1605–1612. DOI: 10.1002/jmv.26514. 30. Muñoz-Basagoiti J., Perez-Zsolt D., León R. et al. Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. J Dent Res. 2021:220345211029269. DOI: 10.1177/00220345211029269. 31. Urakawa R., Inubushi J., Tobata H. et al. Effects of Diluents, Saliva and Other Organics on the Microbicidal Activity of Cetylpyridinium Chloride and Povidone-iodine. Biocontrol Sci. 2020;25(2):45–53. DOI: 10.4265/bio.25.45. 32. Anderson E.R., Patterson E.I., Richards S. et al. Virucidal activity of CPC-containing oral rinses against SARS-CoV-2 variants and are active in the presence of human saliva. bioRxiv. DOI: 10.1101/2021.08.05.455040. 33. Statkute E., Rubina A., O’Donnell V.B. et al. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro. bioRxiv. DOI: 10.1101/2020.11.13.381079. 34. Ellinger B., Bojkova D., Zaliani A. et al. A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Sci Data. 2021;8(1):70. DOI: 10.1038/s41597-021-00848-4. 35. Komine A., Yamaguchi E., Okamoto N. et al. Virucidal activity of oral care products against SARS-CoV-2 in vitro. J Oral Maxillofac Surg Med Pathol. 2021;33(4):475–477. DOI: 10.1016/j.ajoms.2021.02.002. 36. Koch-Heier J., Hoffmann H., Schindler M. et al. Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro. Microorganisms. 2021;9(3):521. DOI: 10.3390/microorganisms9030521. 37. Seneviratne C.J., Balan P., Ko K.K.K. et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021;49(2):305–311. DOI: 10.1007/s15010-020-01563-9. 38. Eduardo F.P., Corrêa L., Heller D. et al. Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial. Heliyon. 2021;7(6):e07346. DOI: 10.1016/j.heliyon.2021.e07346. 39. Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) (AMPoL) (Electronic resource.) URL: https://clinicaltrials.gov/ct2/show/NCT04409873. 40. Pinky L., Dobrovolny H.M. SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial? J Med Virol. 2020;92(11):2623–2630. DOI: 10.1002/jmv.26098. 41. Monitoring data of infectious morbidity. (Electronic resource.) URL: https://www.iminfin.ru/areas-of-analysis/health (access date: 09/28/2021) (in Russ.). 42. Mukherjee P.K., Esper F., Buchheit K. et al. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 201714;17(1):74. DOI: 10.1186/s12879-016-2177-8. 43. Wu M.H., Cheng Y., Wang T.Y. et al. Clinical observation on the treatment of acute simple pharyngitis with cetylpyridinium chloride buccal tablets. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;33(5):466–468. DOI: 10.13201/j.issn.1001-1781.2019.05.021. 44. LeBel G., Vaillancourt K., Morin M.P. et al. Antimicrobial Activity, Biocompatibility and Anti-inflammatory Properties of Cetylpyridinium Chloride-based Mouthwash Containing Sodium Fluoride and Xylitol: An In Vitro Study. Oral Health Prev Dent. 2020;18(1):1069–1076. DOI: 10.3290/j.ohpd.b871071. 45. Chen H.Q., Zhang Z.H., Zhou L. et al. Effect of cetylpyridinium chloride Buccal Tablets on perioperative application of OSAHS patients. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017;31(14):1123–1126. DOI: 10.13201/j.issn.1001-1781.2017.14.018. 46. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19): Temporary guidelines of the Ministry of Health of Russia. Version 12 (09.21.21). (Electronic resource.) URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12. pdf (access date: 28.09.2021) (in Russ.). 47. Melekhina E.V., Gorelov A.V., Music A.D. Clinical features of the course of COVID-19 in children of different age groups. Literature review by early April 2020. Practical issues of pediatrics. 2020;15(2)7–20. DOI: 10.20953 / 1817-7646-2020-2-7-20 (in Russ.). 48. Lobanov Yu.F., Prokudina M.P., Strozenko L.A. et al. Russian Pediatric Journal. 2021;24(4):265 (in Russ.). 49. Gorelov A.V., Nikolaeva S.V., Akimkin V.G. New coronavirus infection COVID-19: features of the course in children in the Russian Federation. Pediatrics. Journal them. G.N. Speransky. 2020;99(6):57–62. DOI: 10.24110 / 0031-403X-2020-99-6-57-62 (in Russ.). 50. Galindo R., Chow H., Rongkavilit C. COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am. 2021;68(5):961–976. DOI: 10.1016/j.pcl.2021.05.004. 51. Chua P.E.Y., Shah S.U., Gui H. et al. Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: a systematic review and meta-analysis of observational studies. J Investig Med. 2021;69(7):1287–1296. DOI: 10.1136/jim-2021-001858. 52. Wang Z., Deng H., Ou C. et al. Clinical symptoms, comorbidities and complications in severe and non-severe patients with COVID-19: A systematic review and meta-analysis without cases duplication. Medicine (Baltimore). 2020;99(48):e23327. DOI: 10.1097/MD.0000000000023327. 53. Al-Beltagi M., Saeed N.K., Bediwy A.S., El-Sawaf Y. Paediatric gastrointestinal disorders in SARS-CoV-2 infection: Epidemiological and clinical implications. World J Gastroenterol. 2021;27(16):1716–1727. DOI: 10.3748/wjg.v27.i16.1716. 54. Badal S., Thapa Bajgain K., Badal S. et al. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: A systematic review and meta-analysis. J Clin Virol. 2021;135:104715. DOI: 10.1016/j.jcv.2020.104715. 55. Features of clinical manifestations and treatment of a disease caused by a new coronavirus infection (COVID-19) in children: methodological recommendations of the Ministry of Health of Russia. Version 2 (07/03/2020). (Electronic resource.) URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_%D0%B4%D0%B5%D1%82%D0 % B8_COVID-19_v2.pdf (access date: 28.09.2021) (in Russ.). 56. Alekseeva E.I., Antsiferov M.B., Aronov L.S. and others. The procedure for the management of children with acute respiratory infections, including COVID-19, who are on outpatient treatment in medical institutions of the state health system of the city of Moscow. Ed. A.I. Khripuna. M .: GBU "NIIOZMM DZM", 2021 (in Russ.). 57. Zakharova I.N., Geppe N.A., Sugyan N.G. et al. Topical etiotropic drugs in the treatment of infectious and inflammatory diseases of the pharynx in preschool children. Results of a multicenter randomized clinical trial. Russian otorhinolaryngology. 2021;20(1):99–113. DOI: 10.18692 / 1810-4800-2021-1-99-113 (in Russ.). 58. Gorelov A.V., Usenko D.V., Antonova L.P. and others. Prospects for the use of combined preparations of lysozyme in COVID-19 Effective pharmacotherapy. 2021;17(24):12–17. DOI: 10.33978 / 2307-3586-2021-17-24-12-17 (in Russ.). 59. Huffnagle G.B., Dickson R.P., Lukacs N.W. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017;10(2):299–306. DOI: 10.1038/mi.2016.108. 60. Man W.H., Clerc M., de Steenhuijsen Piters W.A.A. et al. Loss of Microbial Topography between Oral and Nasopharyngeal Microbiota and Development of Respiratory Infections Early in Life. Am J Respir Crit Care Med. 2019;200(6):760–770. DOI: 10.1164/rccm.201810-1993OC. 61. Geppe N.A., Karpova E.P., Dronov I.A. other Topical drugs for the treatment of acute non-streptococcal tonsillopharyngitis in children: results of a multicenter study. Bulletin of otorhinolaryngology. 2020;85(6):89–94. DOI: 10.17116 / otorino20208506189 (in Russ.). 62. Zheng J., Gänzle M.G., Lin X.B. et al. Diversity and dynamics of bacteriocins from human microbiome. Environ Microbiol. 2015;17(6):2133–43. DOI: 10.1111/1462-2920.12662. 63. Radford J.R., Beighton D., Nugent Z. et al. Effect of use of 0.05% cetylpyridinium chloride mouthwash on normal oral flora. Journal of Dentistry. 1997; 25(1):35–40. DOI: 10.1016/s0300-5712(95)00116-6.